Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)

Completed · Phase 3 · Has a placebo group

Conditions studied: Chronic Obstructive Pulmonary Disease (COPD)

In brief

The aim of the study is to investigate the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Roflumilast will be administered orally once daily in the morning at one dose level. The study duration will last up to 56 weeks. The study will provide further data on safety and tolerability of roflumilast. For additional information (for US patients only) see www.COPDSTUDY.net or dial 866-788-2673 (toll free).

Key facts

Study ID

NCT00297102

Run by

AstraZeneca

People needed

1523

Starts

2006-02-01

Expected to finish

2008-09-01

Last updated by the study team

2017-01-16

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Altana Pharma/Nycomed Investigational Site — Los Angeles, California, United States
• Altana Pharma/Nycomed Investigational Site — Los Angeles, California, United States
• Altana Pharma/Nycomed Investigational Site — Palmdale, California, United States
• Altana Pharma/Nycomed Investigational Site — Rancho Mirage, California, United States
• Altana Pharma/Nycomed Investigational Site — San Diego, California, United States
• Altana Pharma/Nycomed Investigational Site — Bay Pines, Florida, United States
• Altana Pharma/Nycomed Investigational Site — Miami, Florida, United States
• Altana Pharma/Nycomed Investigational Site — Panama City, Florida, United States
• Altana Pharma/Nycomed Investigational Site — Atlanta, Georgia, United States
• Altana Pharma/Nycomed Investigational Site — Marietta, Georgia, United States
• Altana Pharma/Nycomed Investigational Site — Hines, Illinois, United States
• Altana Pharma/Nycomed Investigational Site — South Bend, Indiana, United States
• Altana Pharma/Nycomed Investigational Site — Lebanon, Kentucky, United States
• Altana Pharma/Nycomed Investigational Site — Metairie, Louisiana, United States
• Altana Pharma/Nycomed Investigational Site — New Orleans, Louisiana, United States
• Altana Pharma/Nycomed Investigational Site — Slidell, Louisiana, United States
• Altana Pharma/Nycomed Investigational Site — Sunset, Louisiana, United States
• Altana Pharma/Nycomed Investigational Site — Bangor, Maine, United States
• Altana Pharma/Nycomed Investigational Site — Baltimore, Maryland, United States
• Altana Pharma/Nycomed Investigational Site — North Dartmouth, Massachusetts, United States
• Altana Pharma/Nycomed Investigational Site — Edina, Minnesota, United States
• Altana Pharma/Nycomed Investigational Site — Minneapolis, Minnesota, United States
• Altana Pharma/Nycomed Investigational Site — Chesterfield, Missouri, United States
• Altana Pharma/Nycomed Investigational Site — St Louis, Missouri, United States
• Altana Pharma/Nycomed Investigational Site — Fullerton, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.